Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Is procalcitonin a good predictor for in-hospital mortality in infective endocarditis?
Session:
SESSÃO DE POSTERS 15 - ENDOCARDITE INFECIOSA 2
Speaker:
Rodrigo Neves Brandão
Congress:
CPC 2025
Topic:
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Theme:
16. Infective Endocarditis
Subtheme:
16.2 Infective Endocarditis – Epidemiology, Prognosis, Outcome
Session Type:
Cartazes
FP Number:
---
Authors:
Rodrigo Neves Brandão; Filipa Gerardo; Carolina Mateus; Inês Pereira de Miranda; Mara Sarmento; Tiago Mesquita; Márcio Madeira; Miguel Borges Dos Santos; Carlos Morais
Abstract
<p><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif"><strong><u>Background: </u></strong><span style="font-size:10.0pt">Infective endocarditis (IE) is a disease with a high mortality rate. Procalcitonin (PCT) is an important marker of bacterial infection and systemic inflammation, and its potential role as a predictor of mortality for some diseases has been increasingly studied over the years, making it a potentially important future biomarker.</span></span></span></p> <p><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif"><strong><u>Objective</u></strong><span style="font-size:10.0pt">: This study aimed to assess the role of procalcitonin as a predictor of mortality in patients with infective endocarditis.</span></span></span></p> <p><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif"><strong><u>Methods: </u></strong><span style="font-size:10.0pt">We conducted a retrospective single center analysis of patients hospitalized with infective endocarditis diagnosis from 2017-2022. Binary logistic regression was used to assess the association between procalcitonin levels and mortality, adjusting for other clinical and laboratory variables, including age, comorbidities, presence or absence of local complications and vegetation size. </span></span></span></p> <p><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif"><strong><u>Results and discussion: </u></strong><span style="font-size:10.0pt">From a total of 89 patients, 69% were male and the mean age was 69.9 ±12.6 years. From the latter, 73% had hypertension, 23% type 2 diabetes, 32% atrial fibrillation and 38% history of valve disease (either intervened or not intervened). Our data revealed that procalcitonin levels were not significantly associated with mortality in infective endocarditis (p = 0.35), with an OR of 0.9, indicating a non-significant and even irrelevant decrease in the odds of mortality for each unit increase in procalcitonin levels. The overall model, including procalcitonin and other clinical variables, was also non-significant (p = 0.7), suggesting that none of the predictors included in the model, collectively, could significantly predict mortality in this cohort.</span></span></span></p> <p><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif"><strong><u>Conclusions:</u></strong><strong><u> </u></strong><span style="font-size:10.0pt">Our findings suggest that procalcitonin does not significantly predict mortality in patients with infective endocarditis, as no statistically significant association was found between PCT levels and patient outcomes. The non-significance of the overall model further indicates that other factors not included in this analysis may be more strongly associated with mortality in this patient population. Further studies with larger sample sizes and consideration of additional biomarkers are warranted to better understand the prognostic role of procalcitonin and other potential predictors in infective endocarditis.</span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site